BioInsights - Manufacturing of hematopoietic stem cell gene therapies: opportunities for process automation

Manufacturing of hematopoietic stem cell gene therapies: opportunities for process automation

Cell & Gene Therapy Insights 2021; 7(11), 1673–1684

10.18609/cgti.2021.223

Published: 20 December 2021
Expert Insight
Carlotta Peticone, Emma Chan

Genetic medicines are being investigated in the context of a range of different diseases, and in some instances have successfully been commercialized. However, challenges in the manufacturing process have the potential to limit the applications of these approaches to treat an even broader number of diseases. The bioprocessing industry, which historically has been focused on large-scale production of biologics, has recently seen a shift of interest and an increasing number of bespoke solutions emerging for the autologous cell and gene therapy field. Several technologies are now available to automate production, either focusing on individual manufacturing steps or providing a combined platform approach. Here, a review of state-of-the art technologies for the manufacturing of autologous cell and gene therapy products is provided.